Draganfly Leverages DealMaker for Reg A and Post-IPO Warrants

January 17, 2023

Draganfly Case Study

$16.48M

Raised through Reg A+

2,348

New investors onboarded

NASDAQ

Successfully uplisted

100%

Digital warrant processing

Advanced UAV Technology Leader

Draganfly is a leading provider of advanced aerial imaging technology and unmanned aerial vehicles (UAVs). The company's state-of-the-art UAVs are used in a wide range of applications, including mapping, surveying, and inspection.

Draganfly was already listed on the OTC market when it decided to raise capital through a Reg A+ offering to fuel its growth and expand its technological capabilities.

"From Reg A+, to warrants, to their NASDAQ listing - Draganfly has had an incredibly successful journey for raising capital and acquiring investors."

DPRO

The Capital Raising Challenge

To manage the complex process of raising capital from a large number of retail investors, Draganfly needed a sophisticated and reliable platform. The company faced several distinct challenges:

Managing a large influx of investors and investment funds efficiently
Ensuring accurate allocation of capital for each investor
Handling potential oversubscription without disrupting the offering process
Creating a smooth transition path to a NASDAQ listing
Establishing a system for ongoing warrant exercise processing

Finding a platform that could address all these needs while maintaining compliance and providing a seamless investor experience was critical to Draganfly's capital-raising strategy.

DealMaker's Solution

Draganfly turned to DealMaker, whose platform made it easy to manage the influx of investors and their investment funds. DealMaker's intuitive interface allowed Draganfly to quickly and easily create and manage investment tickets, ensuring that each investor was allocated the correct amount of capital.

"DealMaker helped Draganfly handle the oversubscription of its offering with sophisticated algorithms and a built-in refund management tool that made the refund process seamless."

The success of Draganfly's Reg A+ offering allowed the company to use the momentum of the offering to list on NASDAQ. The marketing that the company did for the Reg A+ offering also helped to generate interest in the company's stock, increasing its visibility among investors.

Impact & Ongoing Partnership

Draganfly's partnership with DealMaker resulted in a highly successful capital raise that provided the foundation for the company's continued growth and NASDAQ listing:

"In addition to using DealMaker to manage its Reg A+ offering, Draganfly is continuing to use the platform to process thousands of warrant exercises as they expire on a rolling basis."

DealMaker is the only platform that currently processes warrant exercises digitally—transforming an incredibly complicated task into a smooth, efficient process. The intuitive interface and powerful tools of DealMaker's technology make it easy to handle these complex processes, ensuring that investors are able to exercise their warrants smoothly and efficiently.

From Reg A+, to warrants, to their NASDAQ listing - Draganfly has had an incredibly successful journey for raising capital and acquiring investors. DealMaker's technology helped to turn complex processes into an easy and intuitive digital interface. As a result, Draganfly has been able to raise the capital it needs to continue its growth and expansion, and to increase its visibility among investors.

Key Achievements

Successful $16.48M capital raise through Reg A+ offering
Onboarding of 2,348 new investors
Efficient management of offering oversubscription
Seamless uplisting to NASDAQ (Ticker: DPRO)
Ongoing digital processing of warrant exercises
Enhanced visibility and credibility in the market

‍

DealMaker and its affiliates neither offer investment advice or analysis nor endorse or recommend investments in any company or the suitability of an investment for any particular investor. The information on our website regarding any company or in a website post is based on publicly available information or directly from the subject company. DealMaker and its affiliates make no representation or warranty as to the adequacy, accuracy, or completeness of such information. Any comments expressed herein are our own, are not intended as investment advice, and are subject to change without notice. Website posts have been prepared solely for informative purposes and are not a solicitation of an offer to buy or an offer to sell any security.

Monogram Case Study - DealMaker (Embed)

When VCs said no, Monogram turned to retail investors. That decision powered their rise from startup to publicly traded company—and even helped them raise an additional $13M privately after their Nasdaq debut.

The Challenge: Raising Capital on Their Terms

The Challenge: Raising on Their Terms

Monogram Technologies was founded with a bold vision: to revolutionize orthopedic surgery with a robotic joint replacement system using custom 3D-printed joints. The market for this technology is massive—approximately $19.6 billion, with over 1 million knee replacements per year. But it's a capital-intensive, regulation-heavy space—and traditional VCs weren't biting.

Instead of compromising, co-founders Dr. Doug Unis and Ben Sexson went all-in on a different path: retail capital. Why?

Control and ownership: Not only were they able to raise the capital they needed to grow the business—they did it on their own terms.
Long-term asset: They wanted to build an army of true believers who wanted to see the company succeed and would continue to reinvest over the years.
A value-add network: Raising from retail allowed Monogram to amass a waiting list of thousands of patients eager to participate in future trials.
Aligned incentives: Their mission to improve patient outcomes and build a better future for those struggling with joint pain resonated with retail investors.

The Power of Retail: Monogram's Capital Journey

Start Date	End Date	Type	Platform	Amount Raised	# Investors
3/13/19	3/31/20	A+	SeedInvest	$14,588,668	6,000
11/16/20	1/16/21	A+	StartEngine	$2,965,501	8,000
1/17/21	2/18/22	A+	StartEngine	$23,647,853	14,082
7/15/22	3/16/23	CF	DealMaker	$4,673,000	2,249
3/1/23	4/8/23	A+	Republic	$232,275	120
3/1/23	5/23/23	A+	DealMaker	$15,958,364	5,198
5/18/23	-	Nasdaq listing
7/24	10/24	Unit Offering	DealMaker	$12,990,103	2,745

Monogram Capital Raise Timeline

Monogram's first direct-to-investor raise was a $14.6M round in 2019. Since then, Monogram has raised retail capital six additional times, using Reg A+ as a springboard to a Nasdaq listing in 2023.

Each raise brought in new believers—and more importantly, kept bringing them back. That's the long-term power of retail capital. It's not just one campaign—it's a compounding asset that grows with the business.

$80M+

Raised across seven campaigns

~40,000

Investors championing Monogram's vision

20%

Of each raise came from previous investors

Marketing Excellence

DealMaker Reach provided strategic investor acquisition services, helping Monogram connect with the right audience through high-impact channels.

Premium Publications

Targeted campaigns in premium publications like Morning Brew captured qualified investors

High-Engagement Webinars

Engaging events that generated over $4.3 million in investments

Community Building

Strategic approaches that fostered a loyal shareholder base

Investment Momentum

Innovative approaches that amplified investment momentum

Monogram's Journey to Success

Monogram's journey has been defined by relentless innovation, strategic fundraising, and breakthrough advancements in robotic-assisted joint replacement. From early-stage research to a Nasdaq listing and beyond, Monogram's milestones reflect its evolution into a pioneering force in orthopedic surgery:

Filed its first patent application in 2017
Conducted clinical studies at UCLA and University of Nebraska
Expanded the team with key hires
Attracted a top-tier advisory board to guide clinical innovations
Signed their first distribution partnerships
Made headlines with cutting-edge live demonstrations
Secured 501(k) FDA clearance for the mBôs surgical system

Nasdaq Debut & Beyond

In May 2023, Monogram Orthopaedics successfully listed on the Nasdaq—a significant milestone offering liquidity and growth opportunities for the company.

For most companies, that would be the end of their story in the private markets. But for Monogram, it was just the beginning of a new chapter.

Public perception says you can't raise privately post-IPO. Monogram proved that wrong.

Defying conventional fundraising norms, Monogram raised an additional $13 million from private investors, powered by DealMaker. This move highlighted the power of a dedicated investor community and provided additional strategic growth capital. Meanwhile, strategic digital marketing for the private offering helped boost the public share price—a win-win for the company and its investors, both public and private.

This was retail capital at its best: strategic, repeatable, and aligned.

One vision. Zero compromises.

This wasn't a one-time raise. It was a multi-year capital strategy.

Retail capital helped Monogram:

Go from concept to commercialization without relying on VCs
Retain ownership and control in a high-burn industry
Build a base of loyal shareholders who invested not once, but over and over again
Uplist to the Nasdaq, and still keep raising post-IPO

This is what makes retail capital different. It doesn't expire—it compounds. And DealMaker is built to maximize that long-term value.

Ready to Raise Capital on Your Terms?

Whether you're pre-revenue or post-IPO, DealMaker gives you the infrastructure, support, and strategy to raise from the people who believe in you most.

Explore Raising Capital with DealMaker